硼替佐米治疗初治多发性骨髓瘤成功病例报告(附文献复习)

目的:探讨蛋白酶体抑制剂——硼替佐米对初治多发性骨髓瘤的疗效及对移植造血干细胞采集的影响。方法:对一例初发的中年男性多发性骨髓瘤患者使用硼替佐米 地塞米松 反应停(VTD)的方案进行化疗,获得缓解后采集外周血造血干细胞。结果:应用以硼替佐米为基础的方案治疗3个疗程后,患者即获得完全缓解;完成4个疗程化疗后成功采集足够数量的外周血造血干细胞;完成6个疗程化疗后,进入维持治疗,至今已完全缓解17个月。治疗过程中除恶心、呕吐外无其他明显不良反应。结论:硼替佐米用于初治多发性骨髓瘤有良好的治疗效果,不良反应少,不影响造血干细胞采集。

Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review

Objective:To evaluate the effect of proteasome inhibitor(bortezomib)on an early multiple myeloma and the influence on the collection of peripheral hematopoietic stem cells.Methods:An adult patient with previously untreated multiple myeloma was treated by bortezomib based regimen including bortezomib,dexamethasone and thalidomide(VTD).After obtaining complete remission(CR),peripheral hematopoietic stem cells were collected for transplantation.Results:After 3 courses of treatments,the patient achieved complete remission successfully.Enough peripheral hematopoietic stem cells were harvested after four courses of treatments.The patient has received maintenance therapy for seventeen months after completing the six courses of treatments,and was still in complete remission.There were no obvious adverse effects except nausea and vomiting.Conclusion:Bortezomib was effective for newly cases with multiple myeloma and with less adverse effects,and was well tolerated.Moreover,it had no negative influence from collection of the peripheral hematopoietic stem cells.